Darius Kharabi's most recent trade in Kala Pharmaceuticals Inc was a trade of 20,806 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on Oct. 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 0.83 per share. | 22 Oct 2025 | 20,806 | 41,760 (0%) | 0% | 0.8 | 17,269 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 4.01 per share. | 24 Jun 2025 | 4,511 | 62,566 (0%) | 0% | 4.0 | 18,089 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 3.74 per share. | 03 Jun 2025 | 730 | 67,077 (0%) | 0% | 3.7 | 2,730 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 10,100 | 69,828 (0%) | 0% | 0 | Common Stock | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 2,021 | 67,807 (0%) | 0% | 7.6 | 15,420 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 5,158 | 59,728 (0%) | 0% | 4.8 | 24,501 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 231 | 64,886 (0%) | 0% | 6.1 | 1,407 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 4,600 | 66,502 (0%) | 0% | 0 | Common Stock | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 04 Jan 2024 | 1,385 | 65,117 (0%) | 0% | 6.7 | 9,321 | Common Stock |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 432 | 432 | - | - | Stock Option (Right to Buy) | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 9,525 | 15,439 (0%) | 0% | 0 | Common Stock | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 295,657 | 295,657 (0%) | 0% | - | Common Stock | |
| Kala Pharma Inc | Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) |